Ketorolac Tromethamine Injection
Product Images NDC 0487-6232

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ketorolac Tromethamine (NDC 0487-6232). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nephron Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Carton (Carton)

Carton (Carton)
This text provides information on a drug called Ketorolac Tromethamine in an injectable form. It is available in a 60mg/2mL (30mg/mL) concentration. The National Drug Code (NDC) for this medication is 0487-6232:01 and also mentioned NDC 0457-6232.01. The medication is meant for intramuscular use only and is not for sale to consumers. Some characters in the text are not recognizable.*
FDA Label Image

Gi (Gi Experiences)

Gi (Gi Experiences)
This is a list of possible side effects experienced by people taking a medication, including gastrointestinal symptoms like abdominal pain, constipation, and diarrhea, along with other symptoms like dizziness, headaches, and abnormal renal function. The incidence of headaches is higher than 10%.*
FDA Label Image

Sleeve Label (Sleeve)

Sleeve Label (Sleeve)
This is a description for Ketorolac Tromethamine Injection, USP. It contains 60mg of ketorolac tromethamine in 2ml (30mg/ ml) for intramuscular use only. It should be stored at a temperature of 20°C to 25°C (68°F to 77°F) and protected from light. This injection is sterile and nonpyrogenic, so unused portions should be discarded. Recommended dosage instructions can be found in the package insert. This product is made by Nephron Pharmaceuticals Corporation in West Columbia, SC. No further meaningful text is available.*
FDA Label Image

Table 1 (Table 1)

Table 1 (Table 1)
The text provides a table (Table 1) of approximate average pharmacokinetic parameters for oral, intramuscular, and intravenous doses of Ketorolac Tromethamine in normal volunteer subjects. The parameters include bioavailability, maximum concentration, steady-state concentration, trough plasma concentration, plasma protein binding, volume of distribution, % dose metabolized, % dose excreted in urine, and time to peak plasma concentration. The mean values are presented in the table along with the standard deviation for each parameter.*
FDA Label Image

Table 3 (Table 3)

Table 3 (Table 3)
This is a table showing the incidence of clinically serious gastrointestinal bleeding related to age, total daily dose, and history of previous ulcer, perforation or bleeding (PUB) after up to 5 days of treatment with Ketorolac Tromethamine Injection. The table is divided into two sections: one for adult patients without a history of PUB, and one for adult patients with a history of PUB. The table shows the incidence of bleeding at different age ranges and total daily doses of Ketorolac Tromethamine Injection.*
FDA Label Image

Ifu

Ifu
These are instructions for using Ketorolac Tromethamine Injection, USP with a Luer-Lock Vial. The instructions include twisting off the cap to expose the Luer-Lock fitting, drawing the plunger back on the syringe, connecting the syringe to the vial using the Luer-Lock connection, charging the vial with air by depressing the plunger, pointing the syringe up and drawing the product into it, disconnecting the syringe from the vial, and discarding any unused portion.*
FDA Label Image

Luer Lock

Luer Lock
FDA Label Image

Figure 1 (Structure)

Figure 1 (Structure)
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.